肺表面活性物质应用于新生儿呼吸窘迫综合征预防及治疗

目的探讨肺表面活性物质(PS)预防及治疗新生儿呼吸窘迫综合征(NRDS)的有效性及临床价值。方法29例早产儿气管内滴注单剂预防量PS,并与15例确诊NRDS后用PS的早产儿进行临床对照研究。结果预防组在氧疗时间、机械通气时间、住院时间、住院费用方面与治疗组有显著性差异,死亡率无明显差别,预防组及治疗组血气指标均明显改善。结论PS预防性给药可改善早产儿临床症状及血气指标,降低住院总费用,缩短氧疗时间、机械通气时间和住院天数,减少并发症,值得广泛推广。

PREVENTING PREMATURE INFANT NEONATAL RESPIRATORY DISTRESS SYNDROME WITH PULMONARY SURFACTANT

Objective To study the efficacy and clinical value of pulmonary surfactant on premature infant’s hyaline membrane disease. Methods Twenty-nine premature infants were received treatment of PS by injected into trachea with single dose and were compared with fifteen cases of the newborn infants diagnosed as HMD. ResultsThe time of inhaled oxygen and mechanical ventilation, and the time of inpatient in prevented group were significantly shorter than the contrasted group(p<0.05).The clinical symptoms and results of blood gas analysis in two groups were improved. There was no difference of mortality rate of NRDS between the two groups (p>0.05). Conclusion The therapy prevented for premature by pulmonary surfactant may improve clinical symptom of premature, shorter the time of inpatient and the duration of mechanical ventilation of premature infant. It is benefit for reducing complications. So it is worthy to be widely promoted at subordinate hospitals.